Bridging the Gap: Why Diversity Action Plans Are Critical in Clinical Trials

With the FDA’s Diversity Action Plan taking effect in July 2025, clinical trials must move beyond acknowledgment to real action. Addressing past injustices and present biases is essential to building trust, ensuring inclusivity, and improving healthcare for all.
How to Prepare for FDA-Mandated Clinical Diversity Action Plans (DAPs)

Understanding FDA’s Guidance on Diversity Action Plans (DAPs) is vital for health equity in clinical trials. As DAPs become mandatory, sponsors must adapt recruitment strategies for inclusivity.